Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885395 | 1.00 | NFE2L2 (0.50) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL73226 | 1.00 | NFE2L2 (0.50) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL17862090 | 0.85 | NFE2L2 (0.59) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL9663338 | 0.82 | NFE2L2 (0.46) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL7423750 | 0.82 | NFE2L2 (0.46) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL3873229 | 0.78 | NPC1 (0.44) | NFE2L2 | |
| SCHEMBL73286 | 0.78 | AHR (0.50) | NFE2L2PTGS1FBP1GRIK1GRIK2 | |
| SCHEMBL73285 | 0.78 | AHR (0.50) | NFE2L2PTGS1FBP1GRIK1GRIK2 | |
| SCHEMBL11701545 | 0.76 | NFE2L2 (0.50) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL11701550 | 0.76 | NFE2L2 (0.50) | NFE2L2HSD11B1APPPTGS1FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121759017-A | Preparation method of UV (ultraviolet) curing heat-preservation coating | 菏泽市仟彩涂料有限公司 | 2026-03-31 | — | — | CN | disclosed |
| CN-120329772-B | UV (ultraviolet) curing heat-preserving paint and preparation method thereof | 菏泽市仟彩涂料有限公司 | 2025-12-12 | — | — | CN | disclosed |
| CN-120329772-A | UV (ultraviolet) curing heat-preserving paint and preparation method thereof | 菏泽市仟彩涂料有限公司 | 2025-07-18 | — | — | CN | disclosed |
| CN-118697737-A | Application of piperlonguminine analogue compound in preparation of medicines for treating cervical cancer and/or liver cancer | 赣南医学院第一附属医院 | 2024-09-27 | — | — | CN | disclosed |
| EP-2832728-B1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL IND LTD (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9045422-B2 | Piperidine derivatives with pesticidal properties | SYNGENTA PARTICIPATIONS AG (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2832728-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-20130310399-A1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| US-5344843-A | Carnitine acryltransferase enzyme inhibitors as antiischemic agents and for cardiovascular disorders | HOFFMAN-LA ROCHE INC. (US) | 1994-09-06 | — | — | US | disclosed |
| CN-1087341-A | The assorted norbornane derivative of the ammonia that N-replaces, preparation and its purposes | BASF AG (DE) | 1994-06-01 | — | — | CN | disclosed |
| EP-0347766-B1 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | THOMAE GMBH DR K (DE) | 1994-05-25 | — | — | EP | disclosed |
| WO-1994000458-A1 | N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATES USEFUL AS NEUROLEPTIC AGENTS, ETC. | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |
| WO-1994000445-A1 | SUBSTITUED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATES USEFUL AS INTERMEDIATE PRODUCTS | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |
| EP-0512352-A2 | Substituted carboxylic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-11-11 | — | — | EP | disclosed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0347766-A2 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1989-12-27 | — | — | EP | disclosed |
| US-4265894-A | TREATING PARKINSON'S DISEASE AND ACROMEGALY | GIST BROCADES, N.V. (NL) | 1981-05-05 | — | — | US | disclosed |
| US-4202896-A | DOPAMINERGIC ACTIVITY | GIST-BROCADES N.V. (NL) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | NFE2L2 773/4885HSD11B1 905/4885APP 1240/4885 |
| US-20130310399-A1 | CHEMICAL COMPOUNDS | ACHE, CHRM1, CHRM2 | NFE2L2 2622/4885HSD11B1 4025/4885APP 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.